Antibodies, monoclonal
Showing 26 - 50 of 7,894
SURvival of SEzary Syndrome Over 1998-2020 Period and Its
Not yet recruiting
- Sezary Syndrome
- Cutaneous T Lymphoma
- Standard of care
-
Paris, FranceHôpital Saint-Louis, Service de Dermatologie
Jan 24, 2022
COVID-19 Trial in Beijing (BRII-196 and BRII-198, Placebo)
Completed
- COVID-19
- BRII-196 and BRII-198
- Placebo
-
Beijing, Beijing, ChinaInvestigative Site
Mar 1, 2022
Covid19 Trial in Edinburg, Rio Grande City (BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB)
Recruiting
- Covid19
- BAMLANIVIMAB
- +2 more
-
Edinburg, Texas
- +2 more
Mar 14, 2022
Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)
Not yet recruiting
- Nephrotic Syndrome
- Rituximab Biosimilar ABP 798
- Daratumumab
-
Genova, ItalyIRCCS G. Gaslini
Jan 19, 2023
Infusion Reaction, Monoclonal Antibody Trial in Clovis (Montelukast 10 Mg Oral Tablet)
Recruiting
- Infusion Reaction
- Monoclonal Antibody
- Montelukast 10 Mg Oral Tablet
-
Clovis, CaliforniaCommunity Cancer Institute
Nov 8, 2021
TURN-COVID Biobank: The Dutch Cohort Study for Evaluation of Use
Recruiting
- COVID-19
- casirivimab with imdevimab
- +2 more
-
Amsterdam, Noord Holland, Netherlands
- +3 more
Jan 13, 2022
Consistency of PD-L1 Detecting Method Between E1L3N and 22C3
Completed
- Non Small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Nov 20, 2021
HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)
Completed
- HIV Antibodies
- VRC-HIVMAB091-00-AB
- EDP
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 8, 2022
COVID-19 Trial in China (BRII-196 and BRII-198, Placebo)
Completed
- COVID-19
- BRII-196 and BRII-198
- Placebo
-
Beijing, Beijing, China
- +5 more
Mar 1, 2022
Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
Recruiting
- Verruca Vulgaris
- Healthy
- Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)
-
Sohag, EgyptSohag University
Jun 7, 2022
HIV/AIDS Trial in Orlando, Boston, Houston (PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400)
Completed
- HIV/AIDS
- PGT121 + VRC07-523LS
- PGT121 + VRC07-523LS + PGDM1400
-
Orlando, Florida
- +2 more
May 6, 2022
COVID-19; Isolation of Neutralizing Antibodies for Therapeutics
Active, not recruiting
- SARS-CoV 2
- Blood sampling
-
Grenoble, FranceUniversityGrenobleHospital
Mar 24, 2022
COVID-19 : Neutralizing Human Monoclonal Antibodies Against
Completed
- COVID
- Blood sample
-
Lyon, FranceHôpital de la Croix-Rousse
Jun 17, 2021
Ocrelizumab in Breastmilk
Active, not recruiting
- Multiple Sclerosis
- Clinically Isolated Syndrome
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 21, 2022
Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)
Not yet recruiting
- Human Immunodeficiency Virus
- 3BNC117-LS
- +2 more
-
New York, New York
- +2 more
Jul 12, 2022
Prognostic Value of Protein IMP3 Expression in Cervical Cancer
Active, not recruiting
- Cervical Carcinoma
- immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
- (no location specified)
Jan 5, 2022
Anti-IL-6 Receptor Monoclonal Antibodies on Treatment of
Recruiting
- Rheumatoid Arthritis
- +3 more
-
Barcelona, SpainHospital de la Santa Creu i Sant Pau
Apr 25, 2022
Breast Cancer Trial in Besançon (additional blood sample)
Completed
- Breast Cancer
- additional blood sample
-
Besançon, FranceCentre Hospitalier Régional Universitaire
Apr 15, 2021
Chronic Migraine Trial (KOS (Intranasal kinetic oscillation stimulation))
Not yet recruiting
- Chronic Migraine
- KOS (Intranasal kinetic oscillation stimulation)
- (no location specified)
Apr 14, 2022
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy Trial in Los Angeles (Clazakizumab)
Active, not recruiting
- Kidney Failure, Chronic
- +6 more
-
Los Angeles, CaliforniaNorko Ammerman
Mar 25, 2022